Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors.

Cold Spring Harbor molecular case studies - 1 Aug 2020

Sen Shiraj, Tanaka Ryuma, Khatua Soumen, Zaky Wafik, Janku Filip, Penas-Prado Marta, Weathers Shiao-Pei, Behrang Amini, Roszik Jason, Subbiah Vivek

Abstract excerpt

Although BRAF inhibition has demonstrated activity in BRAFV600 -mutated brain tumors, ultimately these cancers grow resistant to BRAF inhibitor monotherapy. Parallel activation of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway has been implicated as a mechanism of primary and secondary resistance to BRAF inhibition. Moreover, it has been shown specifically that mTOR signaling activation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to TOR Serine-Threonine Kinases

Share to Vemurafenib

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 32843426
DOI: 10.1101/mcs.a005041
PMCID: PMC7476413

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors.PMID 32843426Read ↗

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.Semantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumorsSemantic proximity Read ↗

BRAF Status in Personalizing Treatment Approaches for Pediatric GliomasSemantic proximity Read ↗

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.Semantic proximity Read ↗

Targeted Therapy for BRAF Mutant Brain Tumors.Semantic proximity Read ↗

Targeting BRAF in pediatric brain tumors.Semantic proximity Read ↗

[Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].Semantic proximity Read ↗

Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.Semantic proximity Read ↗

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.Semantic proximity Read ↗

Targeted therapy for BRAFV600E malignant astrocytoma.Semantic proximity Read ↗

Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.